LIBX-A403 (Compound 21) is a highly selective inhibitor of acyl-CoA synthetase long-chain family member 4 (ACSL4) with an IC50 of 0.049 µM. It prevents ACSL4-mediated pro-ferroptotic phospholipid remodeling. LIBX-A403 shows potential for research in cancer, such as triple-negative breast cancer, and neurodegenerative disorders like Parkinsons disease.
Target-Kategorie:
Ferroptosis
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
